TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
34.58
-0.80 (-2.26%)
At close: Apr 28, 2026, 4:00 PM EDT
34.63
+0.05 (0.15%)
After-hours: Apr 28, 2026, 4:59 PM EDT
TG Therapeutics Employees
TG Therapeutics had 399 employees as of December 31, 2025. The number of employees increased by 61 or 18.05% compared to the previous year.
Employees
399
Change (1Y)
61
Growth (1Y)
18.05%
Revenue / Employee
$1,544,579
Profits / Employee
$1,120,749
Market Cap
5.11B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Apellis Pharmaceuticals | 739 |
| Corcept Therapeutics | 730 |
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Xenon Pharmaceuticals | 370 |
| Immunovant | 362 |
TGTX News
- 13 days ago - TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI - GlobeNewsWire
- 5 weeks ago - TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million - GlobeNewsWire
- 7 weeks ago - Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis - GlobeNewsWire
- 7 weeks ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire
- 2 months ago - TG Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance - GlobeNewsWire
- 2 months ago - TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update - GlobeNewsWire